Commentary: Interleukin 2: The gasoline that lit the immunotherapeutic fire von Ripley, R. Taylor

Volltext

Commentary: Drawing the target after shooting the arrow: The importance of trial design von Ripley, R. Taylor

Volltext

Commentary: Filling up my truck from an oil tanker: Can big ‘omic’ data influence our clinical decisions? von Ripley, R. Taylor

Volltext

Commentary: Minimally-invasive thymectomy with minimal concerns von Ripley, R. Taylor

Volltext

Reply: Perioperative transfusion: Immunological beast or scapegoat von Ripley, R. Taylor

Volltext

Bile acid-induced “Minority MOMP” promotes esophageal carcinogenesis while maintaining apoptotic resistance via Mcl-1 von Xu, Yuan, Surman, Deborah R., Diggs, Laurence, Xi, Sichuan, Gao, Shaojian, Gurusamy, Devikala, McLoughlin, Kaitlin, Drake, Justin, Feingold, Paul, Brown, Kate, Wangsa, Danny, Wangsa, Darawalee, Zhang, Xi, Ried, Thomas, Davis, Jeremy L., Hernandez, Jonathan, Hoang, Chuong D., Souza, Rhonda F., Schrump, David S., Taylor Ripley, R.

Volltext

Commentary: Limitations of Data for Primary Pericardial Mesothelioma von Ripley, R. Taylor

Volltext

International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma von Medina, Cristian G, Xu, Yuan, Ripley, R Taylor

Volltext

Commentary: KRAS-mutant lung adenocarcinomas—a work in progress von Corsini, Erin M., Ripley, R. Taylor

Volltext

MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis von Singh, Anand, Bhattacharyya, Nisan, Srivastava, Abhishek, Pruett, Nathanael, Ripley, R. Taylor, Schrump, David S., Hoang, Chuong D.

Volltext

Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy von KEMP, Clinton D, RAO, Mahadev, ZHU, Yuelin J, TAYLOR RIPLEY, R, MATHUR, Aarti, FANG LIU, MAOCHENG YANG, MELTZER, Paul A, MARQUEZ, Victor E, DE RIENZO, Assunta, BUENO, Raphael, SCHRUMP, David S, SICHUAN XI, INCHAUSTE, Suzanne, MANI, Haresh, FETSCH, Patricia, FILIE, Armando, MARY ZHANG, HONG, Julie A, WALKER, Robert L

Volltext

Commentary: To Preserve or Not Preserve (The Lung): That Is the MPM Question von Ripley, R. Taylor

Volltext

Minority MOMP: a toxic, slow demise von Xu, Yuan, Surman, Deborah R., Ripley, R. Taylor

Volltext

Commentary: EGFR mutations lung adenocarcinoma—Is the driver removed with the lobe? von Farmer, Douglas M., Ripley, R. Taylor

Volltext

Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment von Jang, Hee-Jin, Lee, Hyun-Sung, Yu, Wendong, Ramineni, Maheshwari, Truong, Cynthia Y, Ramos, Daniela, Splawn, Taylor, Choi, Jong Min, Jung, Sung Yun, Lee, Ju-Seog, Wang, Daniel Y, Sederstrom, Joel M, Pietropaolo, Massimo, Kheradmand, Farrah, Amos, Christopher I, Wheeler, Thomas M, Ripley, R Taylor, Burt, Bryan M

Volltext

Commentary: New strategies for old techniques von Carrott, Philip W., Ripley, R. Taylor

Volltext

Commentary: Cisplatin-induced nephrotoxicity following cytoreductive surgery and heated intraoperative chemotherapy for malignant pleural mesothelioma von Groth, Shawn S., Ripley, R. Taylor

Volltext

Management of Multiple Ground Glass Opacities before or after Lobectomy von Ripley, R. Taylor, Antonoff, Mara, Huang, James, Suzuki, Kenji, Gibney, Barry C.

Volltext

Commentary: The enemy of good: Wishing we always have randomized data von Ripley, R. Taylor, Burt, Bryan M., Groth, Shawn S.

Volltext

Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma von Ripley, R. Taylor, MD, McMillan, Robert R., MD, MPH, Sima, Camelia S., MD, MS, Hasan, Saad M., BA, Ahmad, Usman, MD, Lou, Feiran, MD, Jones, David R., MD, Rusch, Valerie W., MD, Rizk, Nabil P., MD, Huang, James, MD

Volltext